Kalaris Therapeutics, Inc.
KLRS
$3.08
$0.5220.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 290.98% | 618.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 192.72% | 303.98% | |||
| Operating Income | -192.72% | -303.98% | |||
| Income Before Tax | -100.88% | -199.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -100.88% | -199.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -100.88% | -199.27% | |||
| EBIT | -192.72% | -303.98% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 85.76% | 3.09% | |||
| Normalized Basic EPS | 85.76% | 3.09% | |||
| EPS Diluted | 85.76% | 3.09% | |||
| Normalized Diluted EPS | 85.76% | 3.09% | |||
| Average Basic Shares Outstanding | 1,310.67% | 208.78% | |||
| Average Diluted Shares Outstanding | 1,310.67% | 208.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||